Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab adjunctive treatment in adults with major depressive disorder
2014-005206-37Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Sirukumab adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change from baseline in Hamilton Depression Rating Scale (HDRS17) total score. Started Aug 2015; status: completed.
02
Drugs
sirukumab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2014-005206-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005206-37.